Anika Therapeutics Inc (NAS:ANIK)
$ 17.35 -0.2 (-1.14%) Market Cap: 254.10 Mil Enterprise Value: 219.27 Mil PE Ratio: 0 PB Ratio: 1.42 GF Score: 70/100

Anika Therapeutics Inc Corporate Analyst Meeting Transcript

Sep 18, 2019 / 01:00PM GMT
Release Date Price: $54.32 (-0.31%)
Sylvia Cheung
Anika Therapeutics, Inc. - CFO, Treasurer & Secretary

Good morning, everyone. My name is Sylvia Cheung. I'm the Chief Financial Officer at Anika Therapeutics. On behalf of our entire company, I would like to thank everyone here as well as the online participants for joining us today via webcast.

We'll, of course, be making forward-looking statements during today's presentation. The forward-looking statements are under the Securities Exchange Act of 1934, and I'd like to remind you to take those information in consideration under these statements as well as our filings with the SEC.

Here we have our agenda for today. Looking at the

(technical difficulty)

that the management team will be presenting, our plan is to provide a comprehensive overview of our 5-year strategic growth plan.

I'd like to give a brief introduction of our management presenters. Joseph Darling, our President and CEO, brings over 30 years of leadership and industry experience in a number of leading pharma and medical device companies. Joe would discuss the steps that we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot